In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Dosimetric Stereotactic Radiosurgery Predictors of Long Term Trigeminal Neuralgia Freedom from Treatment Failure

    Final Number:
    1433

    Authors:
    Edward M Marchan MD; John R. Vender MD; Rebecca Cantrell MS DABR; Cargill H. Alleyne MD; Ramon Figueroa MD; Waleed F. Mourad MD PhD

    Study Design:
    Other

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2016 Annual Meeting

    Introduction: Stereotactic radiosurgery (SRS) is a treatment modality for classical trigeminal neuralgia (cTN). Success of SRS in facilitating long term pain control is dependent on maximizing prescribed dose (PD) to the trigeminal nerve. We analyzed several internationally standardized SRS treatment parameters and assessed as a primary endpoint whether either of them would predict freedom from treatment failure (TF).

    Methods: Between 2007-2015, 178 cTN patients underwent Gamma Knife SRS, with a 4 millimeter collimator. Pain before and after SRS was scored as level I-V per the Barrow Neurological Institute (BNI) pain intensity scoring criteria. Pain relief was graded as an improvement to BNI levels I, II, or III from pre-SRS BNI levels IV or V. TF was graded as a return to BNI levels IV or V or need for additional SRS or operative intervention. Time to TF (TTF) was measured. The energy index, conformity index, homogeneity index (HI) [(D2% minus D98%)/D50%], and gradient index were calculated. A statistical model using Cox regression evaluating our primary endpoint was designed comparing a) TF and non-TF patients to determine TF risk.

    Results: Median PD was 80 Gy [range (r): 70-80]. The median follow-up was 15 months (r: 1.5-82). The median time to initial response was 1 month (r: 0.05-5) and the median TTF was 20 months (r: 0-82). Ninety percent reported initial pain relief, and actuarial rates of freedom from TF at 12, 24, 36 and 48 months were 55, 40, 33, and 28%, respectively. Statistical modeling showed that HI was the only treatment parameter that independently predicted time to TF (p=0.0273). Each unit increase in HI had a 88.3% decrease in TF risk (HR: 0.117 95% CI: 0.017-0.788).

    Conclusions: This is the first cTN series showing that optimization of the HI enhances freedom from TF. Incorporation of the HI may be used to guide dosimetric treatment planning in SRS for cTN.

    Patient Care: Incorporation of the HI as part of the decision making in treatment planning may be used to guide future dosimetry in SRS for cTN.

    Learning Objectives: Learn about the importance of the homogeneity index in enhancing freedom from treatment failure in patients treated with SRS for cTN.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy